Lyrus

Heart Health Month | February
February is observed globally as Heart Health Month, a reminder that cardiovascular health remains one of the most critical challenges in modern healthcare.
Heart disease continues to be a leading cause of morbidity worldwide—driven by lifestyle factors, metabolic disorders, ageing populations, and unmet preventive care needs. Addressing this challenge requires more than awareness; it demands robust science, innovation in formulation, and scalable therapeutic solutions.
At Lyrus, we believe meaningful impact begins when we think strategically about patient needs, design formulations with scientific rigour, and deliver quality-driven solutions that support long-term cardiovascular health. As a science-led CDMO, we partner with pharmaceutical companies to advance research, development, and manufacturing of differentiated therapies across cardio-metabolic and preventive healthcare domains.
This Heart Health Month, we reaffirm our commitment to enabling better outcomes through innovation, collaboration, and responsible pharmaceutical development.

&D

Supporting Smoke-Free Futures on World Quit Smoking Day 🚭
Did you know? Smoking claims over 8 million lives yearly, damaging lungs, heart, and accelerating cancer—yet quitting slashes risks dramatically within months.
Key facts: Ni****ne addiction drives 80% of quit failures, but evidence-based therapies like patches, gums, and inhalers boost success by 50-70%.
Lyrus leads with educational commitment and CDMO prowess: We engineer advanced ni****ne replacement therapies (NRTs), smokeless alternatives, and respiratory formulations using NDDS platforms for optimal absorption and compliance. Our cGMP labs ensure rigorous stability testing, impurity profiling, and regulatory dossiers (eCTD, ANDA) for US/EU markets. From pre-formulation to pilot scale, we partner for impactful, patient-centric solutions.
Empower quits, elevate health. Connect with Lyrus' experts today!

Empowering Prevention: Cervical Cancer Awareness Month.
This January, Lyrus and our CSR unit, Bothra Foundation, unite in the fight against cervical cancer—organizing regular screening programs to drive early detection and save lives.​
In parallel, our CDMO expertise scales complex, patient-centric dosage forms through world-class R&D, in-house pilot manufacturing, and strategic MHRA/FDA-approved alliances for seamless portability to regulated markets like US, Europe, and Africa.​
Pharma leaders, partner with us to innovate impactful therapies. Together for healthier futures. &D